AG 2304
Alternative Names: AG-2304Latest Information Update: 29 Dec 2024
Price :
$50 *
At a glance
- Originator Ahn-Gook Pharmaceutical
- Class Antihyperlipidaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hypercholesterolaemia
Most Recent Events
- 05 Dec 2024 Preclinical trials in Hypercholesterolaemia in South Korea (PO)
- 05 Dec 2024 Ahn-Gook Pharmaceuticals plans a phase III trial for Hypercholesterolaemia (PO) in June 2025 (NCT06717360)